IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Forsta AP Fonden

Forsta AP Fonden increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 32,600 shares of the company’s stock after buying an additional 1,900 shares during the quarter. Forsta AP Fonden’s holdings in IDEXX Laboratories were worth $16,470,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of IDEXX Laboratories by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock worth $4,576,476,000 after purchasing an additional 98,387 shares during the period. American Century Companies Inc. grew its stake in shares of IDEXX Laboratories by 46.0% during the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock worth $274,179,000 after purchasing an additional 177,226 shares during the period. International Assets Investment Management LLC grew its stake in shares of IDEXX Laboratories by 52,746.0% during the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company’s stock worth $2,669,890,000 after purchasing an additional 527,460 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of IDEXX Laboratories by 13.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 512,788 shares of the company’s stock worth $249,855,000 after purchasing an additional 59,519 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of IDEXX Laboratories by 12.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 390,565 shares of the company’s stock worth $190,283,000 after purchasing an additional 43,473 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.2 %

Shares of IDXX stock opened at $451.41 on Friday. The stock’s fifty day moving average is $484.62 and its two-hundred day moving average is $489.32. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. The firm has a market capitalization of $37.16 billion, a P/E ratio of 44.69, a PEG ratio of 4.03 and a beta of 1.33. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The company’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.67 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the topic of a number of analyst reports. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target on the stock. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. JPMorgan Chase & Co. dropped their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Finally, Piper Sandler dropped their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $574.13.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.